stoxline Quote Chart Rank Option Currency Glossary
  
Arrowhead Pharmaceuticals, Inc. (ARWR)
18.57  -0.32 (-1.69%)    02-12 18:48
Open: 18.35
High: 18.61
Volume: 1,904,865
  
Pre. Close: 18.89
Low: 17.57
Market Cap: 2,342(M)
Technical analysis
2025-02-12 4:43:05 PM
Short term     
Mid term     
Targets 6-month :  23.6 1-year :  25.5
Resists First :  20.2 Second :  21.84
Pivot price 19.87
Supports First :  17.56 Second :  14.61
MAs MA(5) :  19.57 MA(20) :  19.88
MA(100) :  20.27 MA(250) :  23.63
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  27.8 D(3) :  37.7
RSI RSI(14): 40.3
52-week High :  36.72 Low :  17.04
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ARWR ] has closed below the lower bollinger band by 2.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ARWR ] is to continue within current trading range. It is unclear right now based on current values. 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 18.63 - 18.78 18.78 - 18.88
Low: 17.27 - 17.43 17.43 - 17.54
Close: 18.35 - 18.61 18.61 - 18.79
Company Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Headline News

Wed, 12 Feb 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript - MSN

Tue, 11 Feb 2025
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance

Tue, 11 Feb 2025
abrdn plc Acquires 48,929 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Mon, 10 Feb 2025
Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartz

Mon, 10 Feb 2025
Arrowhead Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Mon, 10 Feb 2025
Earnings Flash (ARWR) Arrowhead Pharmaceuticals Reports Q1 Revenue $2.5M -February 10, 2025 at 04:16 pm EST - Marketscreener.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 125 (M)
Held by Insiders 1.1049e+008 (%)
Held by Institutions 4.4 (%)
Shares Short 9,330 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.2978e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 785 %
Return on Equity (ttm) -40.8 %
Qtrly Rev. Growth 1.965e+007 %
Gross Profit (p.s.) 0
Sales Per Share -163.27
EBITDA (p.s.) 2.1129e+007
Qtrly Earnings Growth -5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -352 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.12
Price to Cash Flow 6.49
Stock Dividends
Dividend 0
Forward Dividend 9.45e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android